| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gold NanoParticles are often used as drug carrier. Has impressive optical properties. Gold nanoparticles (AuNPs) are best treated as a nanomaterial “platform” (theranostic / drug-delivery / energy-enhancement adjunct) rather than a single drug. In oncology, their value comes from physics + delivery: Au strongly absorbs/scatters light (plasmonics) enabling photothermal tumor heating; it is a high-Z material that can amplify radiation dose deposition (radiosensitization); and it can be engineered (size/shape/surface ligands) to accumulate in tumors and carry payloads (drugs, immune agonists, imaging dyes). The main translation constraints are heterogeneous tumor delivery (EPR variability), biodistribution/clearance (often liver/spleen uptake), and the fact that many impressive in-vitro effects depend on exposure levels not always achieved in human tumors. Gold Nanoparticles — Gold nanoparticles (AuNPs; GoldNPs) are engineered nanoscale particles containing elemental gold, commonly formulated as spheres, nanorods, nanoshells, nanoclusters, or gold-coated composite particles and frequently modified with PEG, antibodies, peptides, nucleic acids, or therapeutic payloads. They are best classified as a nanomedicine / theranostic platform rather than as a single pharmacologic drug. Their major oncology value derives from the high atomic number of gold, strong and tunable plasmonic optical absorption, readily functionalized surface chemistry, and the ability of selected formulations to accumulate in tumors. Biological activity is highly dependent on particle size, shape, coating, surface charge, attached payload, intracellular localization, and external energy source; therefore mechanistic findings from one AuNP formulation should not automatically be generalized to other AuNPs. Primary mechanisms (ranked):
Bioavailability / PK relevance: AuNP pharmacokinetics are formulation-dependent rather than describable by a single bioavailability value. Intravenous particles commonly undergo protein-corona formation and substantial mononuclear-phagocyte-system sequestration, particularly in liver and spleen. Particle size, hydrodynamic diameter, surface charge and PEGylation strongly affect circulation time, tumor deposition, intracellular uptake and clearance. Larger nanoshell-type particles may persist in reticuloendothelial organs, whereas ultrasmall gold nanoclusters can be engineered for substantial renal elimination. Tumor accumulation through the enhanced permeability and retention effect is heterogeneous and should not be assumed to provide uniform or deep tumor delivery. In-vitro vs systemic exposure relevance: Direct AuNP concentrations and intracellular loading achieved in cultured cells can substantially exceed or differ from exposure achievable within human tumors after systemic administration. Consequently, pathway findings such as apoptosis, mitochondrial dysfunction, PI3K/Akt inhibition, EGFR inhibition, TrxR suppression or ROS induction should not be generalized to elemental AuNPs unless demonstrated for the specific clinically relevant formulation. Photothermal and radiosensitizing effects are additionally dependent on particle localization and external light or ionizing-radiation geometry rather than conventional systemic drug concentration alone. Clinical evidence status: Small human / investigational platform with formulation-specific clinical evidence. The strongest direct oncology evidence is for intravenously administered gold-silica nanoshells followed by near-infrared focal photothermal ablation of localized prostate cancer. A multicenter feasibility study treated 44 evaluable men and reported negative biopsy within the treated zone in approximately 73% at 12 months while generally preserving urinary and sexual function. Other human studies include phase I CYT-6091 gold-bound TNF delivery and a first-in-human phase 0 trial of the BCL2L12-targeting gold spherical nucleic acid NU-0129 in recurrent glioblastoma. AuNP radiosensitization remains predominantly preclinical. Gold nanoparticles are not established as a general approved anticancer drug; importantly, FDA 510(k) clearance of the AuroLase Laser Delivery Device concerns the laser-delivery hardware and does not constitute approval of AuNPs as a systemic cancer therapeutic. Platform : AuNP, Gold NanoParticles Gold nanoparticles are engineered high-Z nanomaterials used in oncology primarily as (1) photothermal transducers, (2) radiosensitizers, and (3) targeted delivery/theranostic carriers. Effects are strongly dependent on particle size/shape/coating, tumor delivery (EPR/targeting), and whether an external energy source (light, radiation) is applied. Gold Nanoparticle Cancer-Relevant Mechanisms
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis. Mitochondria are organelles within eukaryotic cells that produce adenosine triphosphate (ATP), the main energy molecule used by the cell. For this reason, the mitochondrion is sometimes referred to as “the powerhouse of the cell”. Mitochondria produce ATP through process of cellular respiration—specifically, aerobic respiration, which requires oxygen. The citric acid cycle, or Krebs cycle, takes place in the mitochondria. The mitochondrial membrane potential is widely used in assessing mitochondrial function as it relates to the mitochondrial capacity of ATP generation by oxidative phosphorylation. The mitochondrial membrane potential is a reliable indicator of mitochondrial health. In cancer cells, ΔΨm is often decreased, which can lead to changes in cellular metabolism, increased glycolysis, increased reactive oxygen species (ROS) production, and altered cell death pathways. The membrane of malignant mitochondria is hyperpolarized (−220 mV) in comparison to their healthy counterparts (−160 mV), which facilitates the penetration of positively charged molecules to the cancer cells mitochondria. The MMP is a critical indicator of mitochondrial function, directly reflecting the organelle's capacity to generate ATP through oxidative phosphorylation. |
| 1904- | GoldNP, | AgNPs, | Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis |
| - | in-vitro, | Lung, | H157 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Colon, | HCT15 | - | in-vitro, | Melanoma, | A375 |
| 1901- | GoldNP, | Rad, | The role of thioredoxin reductase in gold nanoparticle radiosensitization effects |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:180 Target#:197 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid